{"disease":{"id":"atherosclerotic-occlusive-disease","name":"Atherosclerotic occlusive disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"bempedoic-acid","indication_name":"Atherosclerotic occlusive disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexletol","generic_name":"BEMPEDOIC ACID","company_name":"Esperion Theraps Inc","drug_phase":"marketed","molecular_target":"ATP-citrate lyase (ACL), Niemann-Pick C1-Like 1 (NPC1L1)","drug_class":"Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"NEXLIZET reduces LDL-C by inhibiting cholesterol synthesis in the liver and absorption in the intestine."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05628948","title":"Vascular Lab Resource (VLR) Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT03064126","title":"RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":440,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}